The newest 2-chloro-trityl chloride resin on the market, for biopharmaceutical companies seeking consistency and control in their manufacturing processes
Rohm and Haas introduces the Ambersynth CTC resin, which has been specifically designed and optimised to produce therapeutic peptides.
This resin was developed to perform equally well when scaled up to production level as it does in research protocols. This product is the newest 2-chloro-trityl chloride resin on the market and is ideal for biopharmaceutical companies who need to meet rigorous standards of consistency and control in their manufacturing processes.
Whether you are producing peptides from a strict solid phase synthetic route or using hybrid techniques combining solid phase and solution phase synthesis, Ambersynth CTC resins have the capacity, loading efficiency and recovery profiles you need to economically produce any amount of product, from grams to tonnes.
When compared to other commercially available resins, Ambersynth CTC is said to demonstrate consistently higher loading efficiencies and post-cleavage recovery yields.
This performance increases production rates and profitability for the peptide manufacturer.
Available in gram to multi-tonne quantities, Ambersynth CTC resin is backed by over 50 years' experience in the pharmaceutical industry and is the clear choice for performance, consistency and value.
